Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 20/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 20/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 20/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 20/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 13/20 | 0.79 |
| ▸ | PDE3A | Q14432 | 13/20 | 0.79 |
| ▸ | PDE1A | P54750 | 10/20 | 0.79 |
| ▸ | PDE1B | Q01064 | 10/20 | 0.79 |
| ▸ | PDE1C | Q14123 | 10/20 | 0.79 |
| ▸ | PDE5A | O76074 | 9/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6441242 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL3805902 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL20756030 | 0.91 | PDE4A (0.83) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL5607953 | 0.90 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7160159 | 0.90 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7159233 | 0.88 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7159230 | 0.88 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL8413178 | 0.87 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7821995 | 0.87 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL6051196 | 0.85 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 403 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260137709-A1 | QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATION DISEASES | ABIVAX (FR) | 2026-05-21 | — | — | US | disclosed |
| US-12624044-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260125397-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12617777-B2 | GPR84 antagonists and uses thereof | Liminal Biosciences Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12606568-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-12594339-B2 | Lipid prodrugs of JAK inhibitors and uses thereof | SEAPORT THERAPEUTICS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-11292792-B2 | Tricyclic CRBN ligands and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| WO-2022060952-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | EXITHERA PHARMACEUTICALS, INC. (US) | 2022-03-24 | — | — | WO | disclosed |
| US-11279690-B2 | Inhibitors of glutaminyl cyclase | VIVORIAN THERAPEUTICS N.V | 2022-03-22 | — | — | US | disclosed |
| US-20220073527-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-10 | — | — | US | disclosed |
| US-20220073528-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-10 | — | — | US | disclosed |
| EP-3964513-A1 | COMBINATION PRODUCTS WITH TYROSINE KINASE INHIBITORS AND THEIR USE | Novartis AG (CH) | 2022-03-09 | — | — | EP | disclosed |
| CN-108218849-B | Novel inhibitors | 维沃永治疗公众有限公司 | 2022-03-01 | — | — | CN | disclosed |
| US-20220040231-A1 | COMBINATION THERAPY OF ARMS AND NATURAL KILLER CELLS | BIOHAVEN THERAPEUTICS LTD. | 2022-02-10 | — | — | US | disclosed |
| EP-3946360-A1 | STAT DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20220023324-A1 | QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATION DISEASES | ABIVAX (FR) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11292792-B2 | Tricyclic CRBN ligands and uses thereof | CRBN, CRKL, CUL4A | PDE4A 4486/4885PDE4B 4527/4885PDE4C 4494/4885 |
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | PDE4A 4881/4885PDE4B 4880/4885PDE4C 4878/4885 |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | PDE4A 4097/4885PDE4B 4018/4885PDE4C 4207/4885 |
| US-20220073528-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | PDE4A 4423/4885PDE4B 4309/4885PDE4C 4376/4885 |
| US-12617777-B2 | GPR84 antagonists and uses thereof | GPR84, GPR88, GPR3 | PDE4A 2887/4885PDE4B 3692/4885PDE4C 3821/4885 |
| US-20220023324-A1 | QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATION DISEASES | NR1H3, NR1H2, NR1H4 | PDE4A 2292/4885PDE4B 2688/4885PDE4C 3120/4885 |
| US-20260125397-A1 | MK2 DEGRADERS AND USES THEREOF | NR2C2, NR3C2, OXER1 | PDE4A 4776/4885PDE4B 4760/4885PDE4C 4800/4885 |
| US-20220040231-A1 | COMBINATION THERAPY OF ARMS AND NATURAL KILLER CELLS | PBK, CD47, ICOS | PDE4A 4385/4885PDE4B 4460/4885PDE4C 4115/4885 |
| US-12624044-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCC1, SMARCA2 | PDE4A 3749/4885PDE4B 3747/4885PDE4C 4029/4885 |
| US-12606568-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCD1, SMARCC1 | PDE4A 2368/4885PDE4B 2822/4885PDE4C 2855/4885 |
| US-20220073527-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | PDE4A 4423/4885PDE4B 4309/4885PDE4C 4376/4885 |
| US-12594339-B2 | Lipid prodrugs of JAK inhibitors and uses thereof | JAK1, JAK3, JAK2 | PDE4A 2691/4885PDE4B 2433/4885PDE4C 2786/4885 |
| US-20260137709-A1 | QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATION DISEASES | NR3C1, NR3C2, NR4A1 | PDE4A 1922/4885PDE4B 2361/4885PDE4C 1960/4885 |
| US-11279690-B2 | Inhibitors of glutaminyl cyclase | QPCT, QPCTL, GLUL | PDE4A 2034/4885PDE4B 2522/4885PDE4C 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.